

CONCISE EXPLANATORY STATEMENT

In accordance with the Administrative Procedures Act, R.I. Gen. Laws § 42-35-2.6, the following is a concise explanatory statement:

AGENCY: Rhode Island Department of Health (the Department)

DIVISION: N/A

RULE IDENTIFIER: 216-RICR-10-10-2

RULE TITLE: Rhode Island Cancer Registry

REASON FOR RULEMAKING: The Rhode Island Department of Health is proposing rulemaking to include a new name for carcinomas in-situ of the cervix and update the Central Cancer Registry Standards and Standards for Oncology Registry Entry to the most recent editions.

ANY FINDINGS REQUIRED BY LAW AS A PREEQUISITE TO THE EFFECTIVENESS OF THE RULE: N/A

TESTIMONY AND COMMENTS:

No objections were received.

CHANGES TO THE TEXT OF THE RULE:

§ 2.2(A)(5)(b) Adds “or high-grade squamous epithelial lesion: HSIL” as an alternative name for carcinomas in-situ of the cervix.

§ 2.4(A) Adds “or high-grade squamous epithelial lesion: HSIL” as an alternative name for carcinomas in-situ of the cervix.

§ 2.4(B)(1) Changes reference of the Central Cancer Registry Standards 2020 version to the 2021 version.

§ 2.4(B)(2) Changes reference of the Standards for Oncology Registry Entry 2021 version to the 2022 version.

REGULATORY ANALYSIS:

In development of this rule, consideration was given to:

- 1) Alternative approaches;
- 2) Overlap or duplication with other statutory and regulatory provisions; and
- 3) Significant economic impact on small business

No alternative approach, duplication or overlap was identified based on available information. RIDOH has determined that the benefits of the rule justify its costs.